within Pharmacolibrary.Drugs.ATC.A;

model A16AX03
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.8,
    Cl             = 5.0 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 500 / 1000000,
    adminCount     = 1,
    Vd             = 0.0002,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.01,
    Tlag           = 15.0
  );

  annotation(Documentation(
    info ="<html><body><p>Sodium phenylbutyrate is an aromatic fatty acid used as a nitrogen scavenger in the management of urea cycle disorders (UCDs). By promoting excretion of excess nitrogen, it is used to treat hyperammonemia due to enzyme deficiencies in the urea cycle. It is an FDA-approved therapy for this indication, and also investigated for possible adjunctive use in other rare metabolic diseases and disorders involving ammonia toxicity.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers, both sexes, after a single oral dose under fasting conditions.</p><h4>References</h4><ol><li><p>Osaka, S, et al., &amp; Hayashi, H (2021). A randomized trial to examine the impact of food on pharmacokinetics of 4-phenylbutyrate and change in amino acid availability after a single oral administration of sodium 4-phenylbutyrarte in healthy volunteers. <i>Molecular genetics and metabolism</i> 132(4) 220–226. DOI:<a href=&quot;https://doi.org/10.1016/j.ymgme.2021.02.002&quot;>10.1016/j.ymgme.2021.02.002</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33648834/&quot;>https://pubmed.ncbi.nlm.nih.gov/33648834</a></p></li><li><p>Phuphanich, S, et al., &amp; Carducci, MA (2005). Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: a dose escalation and pharmacologic study. <i>Neuro-oncology</i> 7(2) 177–182. DOI:<a href=&quot;https://doi.org/10.1215/S1152851704000183&quot;>10.1215/S1152851704000183</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/15831235/&quot;>https://pubmed.ncbi.nlm.nih.gov/15831235</a></p></li><li><p>Collins, AF, et al., &amp; Dover, GJ (1995). Oral sodium phenylbutyrate therapy in homozygous beta thalassemia: a clinical trial. <i>Blood</i> 85(1) 43–49. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/7528572/&quot;>https://pubmed.ncbi.nlm.nih.gov/7528572</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end A16AX03;
